60 degrees pharmaceuticals enrolls first patient in tafenoquine expanded access clinical study for persistent (b. microti) babesiosis

60 degrees pharma (nasdaq: sxtp) begins enrolling patients in a clinical study to evaluate tafenoquine for persistent, relapsing babesiosis treatment.

SXTP Ratings Summary

SXTP Quant Ranking